Investors.modernatx.com

Moderna Advances Multiple Vaccine Programs to Late-Stage …

Moderna's EBV vaccine candidates are designed to tackle multiple EBV-associated conditions, including prevention of IM (mRNA-1189) and MS and post-transplant lymphoproliferative disorder, a subcategory of lymphoma in solid organ transplant patients (mRNA-1195). The Phase 1 trial for mRNA-1189 was designed to test the safety, reactogenicity and

Actived: Just Now

URL: https://investors.modernatx.com/news/news-details/2024/Moderna-Advances-Multiple-Vaccine-Programs-to-Late-Stage-Clinical-Trials/default.aspx

Moderna Achieves Positive Interim Results from Phase 3 Trial of …

In the NextCOVE (NCT05815498) Phase 3 pivotal trial, mRNA-1283 was shown to elicit a higher immune response against both the Omicron BA.4/BA.5 and original virus strains …

Category:  Health Go Health

Moderna Expands the Field of mRNA Medicine with Positive …

Company's flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial; separate Phase 1/2 data demonstrated higher HAI titers than Fluzone HD Vaccine pipeline …

Category:  Health Go Health

Moderna Announces Clinical and Program Updates at 3rd Annual …

COVID-19 vaccine Phase 2/3 study in children 6 months to under 6 years has successfully met its primary endpoint with robust neutralizing antibody titers similar to adults. …

Category:  Health Go Health

Moderna Announces Positive Phase 1/2 Data from mRNA-1083, …

mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines …

Category:  Health Go Health

Moderna to Provide Business and Pipeline Updates at the 2023 J.P

CAMBRIDGE, MA / ACCESSWIRE / January 3, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) …

Category:  Health Go Health

Moderna Announces Its Global Public Health Strategy

First, Moderna is announcing a commitment to expand its global public health portfolio to 15 vaccine programs targeting priority pathogens [1] that threaten global health, …

Category:  Health Go Health

Moderna’s Commitment to Patient Access in the United States

Moderna’s vaccines have protected the lives of hundreds of millions of people around the world from COVID-19 and have dramatically lessened the burden of the pandemic …

Category:  Health Go Health

Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial …

The increase in 2021 was driven by increased product sales. Product sales for the fourth quarter of 2021 were $6.9 billion from sales of 297 million doses of the Company's …

Category:  Health Go Health

Moderna Reports Third Quarter 2022 Financial Results and …

Product sales for the third quarter of 2022 were $3.1 billion, a decrease of 35%, compared to the same period in 2021, primarily driven by lower sales volume due to the timing …

Category:  Health Go Health

Moderna Reports First Quarter 2022 Financial Results and Provides

First Quarter 2022 Financial Results. Revenue: Total revenue was $6.1 billion for the first quarter of 2022, compared to $1.9 billion for the same period in 2021. The increase in …

Category:  Health Go Health

Moderna Announces the Launch of Global Fellowship Program for …

Initiative to support a new generation of leaders in mRNA therapeutics and vaccine research. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 6, 2021-- Moderna, Inc. (Nasdaq: …

Category:  Health Go Health

Moderna Announces First Participants Dosed in Phase 3 Study of …

mRNA-1010 is Moderna's first seasonal influenza vaccine candidate to enter a Phase 3 trial mRNA-1010 is one of several influenza vaccine candidates being developed in …

Category:  Health Go Health

Moderna Provides Business and Pipeline Updates at 42nd Annual …

Jamey Mock, Chief Financial Officer of Moderna, will present an update on the Company and its pipeline of mRNA development programs on Monday, January 8 th, 2024, at …

Category:  Health Go Health

Moderna Announces Changes to Commercial Organization to …

CAMBRIDGE, MA / ACCESSWIRE / December 12, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced changes to its operating model to bring focus to its short- …

Category:  Health Go Health

Moderna Shares Environmental, Social and Governance Highlights …

Moderna continues development of at least 15 vaccine programs targeting emerging or neglected infectious diseases by 2025 as part of global health program Moderna …

Category:  Health Go Health

Moderna Reports Second Quarter Fiscal Year 2021 Financial …

CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Aug. 5, 2021-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and …

Category:  Health Go Health

Moderna Finalizes Plan for Long-Term Strategic Partnership with …

Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually The ten-year strategic partnership is …

Category:  Health Go Health

Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial …

Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55 Reports full-year revenues of $6.8 billion, GAAP net loss of $(4.7) …

Category:  Health Go Health